# Osimertinib Resistance in Patients With Non-small-cell Lung Carcinoma That Have Progressed.

> **NCT04737382** · NA · UNKNOWN · sponsor: **The Netherlands Cancer Institute** · enrollment: 200 (estimated)

## Conditions studied

- Non-small-cell Lung Carcinoma

## Interventions

- **DIAGNOSTIC_TEST:** biopsy
- **DIAGNOSTIC_TEST:** ctDAN analysis

## Key facts

- **NCT ID:** NCT04737382
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-22
- **Primary completion:** 2024-08-22
- **Final completion:** 2024-08-22
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2023-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04737382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04737382, "Osimertinib Resistance in Patients With Non-small-cell Lung Carcinoma That Have Progressed.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04737382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*